Yury Mareev

2.3K posts

Yury Mareev banner
Yury Mareev

Yury Mareev

@YMareev

cardiologist working in the field of heart failure and electrophysiology and also a researcher in Roberson Center of Biostatistics

Katılım Ağustos 2019
406 Takip Edilen677 Takipçiler
Yury Mareev retweetledi
Marat Fudim, MD MHS
Marat Fudim, MD MHS@FudimMarat·
Not too late to register! Key note speaker--> @NMHheartdoc And many guest speakers @RyanTedfordMD @AminYehyaMD Over 30 exhibitors, Hands on Sessions and ... June 6 in Durham medicine.duke.edu/news/calendar-… @robmentz @Steph_BarnesNP @richa_agarwalMD @manesh_patelMD @DukeHrtFailure
Marat Fudim, MD MHS@FudimMarat

Mark it down ➡️ June 6, 2026 💙 Duke Heart Failure Symposium - The South-East Meeting on ALL around the topic of Heart Function, Implementation and Innovation. World-class faculty and exhibitors are guaranteed! Registration page ⬇️ medicine.duke.edu/education-and-…

English
0
6
11
2.2K
Yury Mareev
Yury Mareev@YMareev·
@hvanspall @novitskiynic @SolovevaAnzhela @bogdienache @MDCaspi @HanCardiomd @F_dalgaard @pmyhre @AmrAbdin10 @SLKristensen @StepanenkoMD @ARakisheva @MarinaTeterinaA @FudimMarat @SABOURETCardio @NEJM @oziadias 10/10 The discussion also covered ways to make AI safer: ▪️ more representative training datasets ▪️ validation across different populations ▪️ regular bias audits ▪️ more diverse research teams Good review on AI bias in healthcare: pubmed.ncbi.nlm.nih.gov/39214762/
English
0
0
5
107
Yury Mareev
Yury Mareev@YMareev·
1/10 During #HFA2026 there was a very interesting debate about the role of AI and large language models in cardiology and healthcare. The discussion was balanced. Not only hype, but also a serious conversation about limitations and risks. 🧵Thread
English
3
2
5
295
Yury Mareev retweetledi
Jan Verwerft
Jan Verwerft@VerwerftJan·
Thank you Marga! A big thank you as well to the fantastic audience for the interactive discussions and enthusiasm, and to the Scientific Committee of for the opportunity to share and discuss CPETecho. @WilfriedMullens
Marga Calvo López@MargaCalvo2

It’s been an absolute pleasure co-chairing this CPET–echo workshop with my colleague and friend @VerwerftJan at #HeartFailure2026. Expanding the implementation of this fascinating technique in our daily practice! 🫀🏃🏼‍♀️

English
0
4
22
1.2K
Yury Mareev retweetledi
Ahmed Bennis MD 🫀
Ahmed Bennis MD 🫀@drbennisahmed·
🫀 RELIEVE-HF results at #HeartFailure26 — a tale of two phenotypes: ✅ HFrEF (EF ≤40%, n=206): Interatrial shunt → improved outcomes ❌ HFpEF (EF >40%, n=302): Interatrial shunt → worse outcomes Key takeaway: device therapy for heart failure is NOT one-size-fits-all. LVEF stratification matters enormously. Presented by William Abraham 🇺🇸 #HeartFailure #RELIEVEHF #Cardiology #HFrEF #HFpEF
Ahmed Bennis MD 🫀 tweet media
English
0
16
51
4.3K
Yury Mareev retweetledi
Novi Yanti Sari
Novi Yanti Sari@slumberbell·
🫀Does the totality of evidence support a role for low-dose #digitalis in modern #HF care? DECISION/DIGIT-HF/DIG study level meta-analysis presented by @kevin_damman #HeartFailure26: 📍Digitalis glycosides was associated with significant ⬇️ the risk of composite of CV death or first worsening HF event 📍Benefit was mainly driven by fewer worsening HF events/hospitalization, without effect in either CV or all-cause mortality 📍Findings were consistent across treatment eras & types of digitalis glycosides 📍Supports reconsideration of low-dose digitalis glycosides as adjunctive therapy in HFrEF/HFmrEF patients @escardio @jozinetm @HFA_President
Novi Yanti Sari tweet mediaNovi Yanti Sari tweet mediaNovi Yanti Sari tweet media
English
0
22
44
2.9K
Yury Mareev retweetledi
Novi Yanti Sari
Novi Yanti Sari@slumberbell·
🫀Diuretic resistance identifies a particularly high-risk HF phenotype. Insights from a post hoc analysis of TRANSFORM-HF presented by @ambarish4786 at #HeartFailure26: 📍~1 in 5 hospitalized HF patients were classified as high risk for diuretic resistance 📍High diuretic resistance risk was associated with: - 79% higher all-cause mortality - 34% higher hospitalization risk - Less improvement in KCCQ-CSS 📍Torsemide vs Furosemide effects similar across diuretic resistance risk strata 📍Loop diuretic selection alone may not overcome the adverse prognosis associated with diuretic resistance @escardio @HFA_President #DiuresisJedi
Novi Yanti Sari tweet mediaNovi Yanti Sari tweet mediaNovi Yanti Sari tweet media
English
1
29
65
4.2K
Yury Mareev retweetledi
Novi Yanti Sari
Novi Yanti Sari@slumberbell·
🫀SUBCUT HF II: is ambulatory subcutaneous furosemide could support earlier discharge in worsening #HF? presented by #RossCampbell at #HeartFailure26: 📍Early discharge supported by SubQ #furosemide increased days alive & out of hospital at 30 days (+4 days vs usual care) 📍Length of index hospitalization was reduced by 5.5 days 📍Benefits remained evident at 60 days 📍Device-related complications were low, with no serious device-related adverse events 📍The strategy may offer a new patient-centered pathway for congestion management outside the hospital @escardio @HFA_President @jozinetm @WilfriedMullens @MarcoMetra
Novi Yanti Sari tweet mediaNovi Yanti Sari tweet mediaNovi Yanti Sari tweet mediaNovi Yanti Sari tweet media
English
1
24
52
3.5K
Yury Mareev retweetledi
Novi Yanti Sari
Novi Yanti Sari@slumberbell·
🫁REDOX-AHF: restrictive vs liberal oxygenation targets in #AHF?🫀 presented by #IdaArentzTaraldsen at #HeartFailure26: 📍Restrictive oxygenation achieved greater decongestion, with larger reductions in lung fluid content measured by ReDS at 24h 📍Restrictive oxygen targets did not worsen dyspnoea, respiratory rate, or patient-reported symptoms 📍Days alive & out of hospital at 30 days were higher in the restrictive oxygenation group @escardio @HFA_President @MarcoMetra @jozinetm @WilfriedMullens
Novi Yanti Sari tweet mediaNovi Yanti Sari tweet mediaNovi Yanti Sari tweet mediaNovi Yanti Sari tweet media
English
1
23
61
4.7K
Yury Mareev retweetledi
Nikolay Novitskiy
Nikolay Novitskiy@novitskiynic·
💦Decongestion is one of the key targets in the treatment of decompensated HF. The results of post-hoc analysis of multicentre RCT “Duel-HF” that compared decongestion by EF and the effects of tora vs furo per os💊 presented today at #HeartFailure2026 @escardio @YMareev
Nikolay Novitskiy tweet media
English
1
4
14
497
Andrew Flett
Andrew Flett@drflett·
BRITISH trial. rct of icd in NICM with scar. At 574 patients.... Nearly half way @SouthamptonCTU @TheBHF
Sara Moscatelli@saramoscatelli7

⚡ ICDs in non-ischaemic cardiomyopathy: time to rethink? For years, the message was simple: 👉 LVEF ≤35% → implant an ICD But in 2026… is it still that straightforward? 🫀 This meta-analysis challenges one of the pillars of heart failure management. 📄 Read the full paper: doi.org/10.1093/eschf/… 💡 What do we know? ICDs still work: 🔻 All-cause mortality ↓ (HR ~0.79) 🔻 Sudden cardiac death ↓ >50% (HR ~0.44) 👉 Strong, consistent relative benefit 🚨 But here’s the key shift… 👉 Absolute benefit is shrinking 📊 As shown in the graphical abstract : Pre-modern era → NNT ~17 DANISH era → NNT ~23 Full GDMT (modelled) → NNT ~43+ 💡 Why? Because modern therapy works: ARNI MRA SGLT2i ➡️ Lower baseline mortality = less room for ICD benefit ⚖️ The paradox 👉 ICDs are still highly effective… 👉 But fewer patients actually benefit 🧬 Who benefits most? Younger patients Higher arrhythmic risk Less competing comorbidities 🚫 Less benefit in: Older patients Those with high CRT use Advanced comorbidity burden 💡 And the elephant in the room… ICDs are not “neutral”: Infections Lead complications Inappropriate shocks Impact on quality of life 👉 When NNT increases, harms matter more ✨ Big takeaways 👉 ICDs are not obsolete 👉 But they are not for everyone anymore 👉 LVEF alone is no longer enough 🚀 The future: Personalized risk stratification Imaging + genetics + AI Smarter selection, not broader use 🧠 Final thought: The question is no longer: ❌ “Does the ICD work?” We know it does. 👉 The real question is: ✅ “Who still truly benefits?” #ICD #HeartFailure #NICM #Cardiology #Arrhythmia #PrecisionMedicine #CardioGenetics #MedEd #CardioTwitter

English
1
0
11
2.2K
Yury Mareev
Yury Mareev@YMareev·
@pmyhre @MDCaspi @HanCardiomd @KaplonCieslicka @AmrAbdin10 @JBauersachsMD @nossikoff @FudimMarat @SABOURETCardio @ARakisheva @bogdienache @MihaiTrofenciuc @baglikov @vass_vassiliou @novitskiynic @MarinaTeterinaA @APisaryuk @SolovevaAnzhela @SLKristensen @StepanenkoMD @DmitryAbramovMD What if we use a more robust endpoint in #ABYSS? Death / MI / stroke / HF hospitalization: HR 1.11 (95% CI 0.88–1.39) Noninferior by SMART-DECISION margin — but right at the edge; fails noninferiority by ABYSS margin. 9/9
Yury Mareev tweet media
English
1
0
1
131

Keşfet

@NMHheartdoc @RyanTedfordMD @AminYehyaMD @robmentz @Steph_BarnesNP @richa_agarwalMD @manesh_patelMD @DukeHrtFailure